Analysis Supports Efficacy of Rodatristat Ethyl Doses in ELEVATE 2 Trial

Analysis Supports Efficacy of Rodatristat Ethyl Doses in ELEVATE 2 Trial

294742

Analysis Supports Efficacy of Rodatristat Ethyl Doses in ELEVATE 2 Trial

A new analysis suggests that the doses of rodatristat ethyl — an investigational therapy for pulmonary arterial hypertension (PAH) — now being evaluated in the Phase 2b ELEVATE 2 clinical trial are likely to reduce levels of the hormone serotonin to an extent that has been demonstrated to be therapeutic in animal models of PAH. These findings were presented at the American Thoracic Society (ATS) 2021 International Conference, held virtually May 14–19. The talk was…

You must be logged in to read/download the full post.